Emapalumab (anti-IFNγ)
Emapalumab (anti-IFNγ) (A2041-GRP)
Products
Description
Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2041 |
| Target | IFN |